Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Nivolumab bij gevorderd hepatocellulair carcinoom: CheckMate 040
jul 2017 | Immuuntherapie, Maag-darm-leveroncologie